Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia

NCT01462175 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01462175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
July 31, 2014
Enrollment
99 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms